$474.7 M

AKBA Mkt cap, 04-Dec-2018
Akebia Therapeutics Net income (Q3, 2018)-26 M
Akebia Therapeutics EBIT (Q3, 2018)-27.8 M
Akebia Therapeutics Cash, 30-Sep-2018162.4 M

Akebia Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

25.4m43.0mwdxefcqufszuzezftuxetqsqxt115.8m230.9m

General and administrative expense

12.5m18.5m22.2m27.0m

Operating expense total

37.9m61.5m138.0m257.9m

EBIT

(37.9m)(61.5m)(136.5m)(79.9m)

Interest expense

206.0k510.0k

Interest income

206.0k510.0k901.0k2.8m

Net Income

(37.0m)(60.7m)(135.7m)(76.9m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

R&D expense

6.2m5.5m6.6m7.5m7.2m15.8m20.2m30.9m31.2m60.0m43.8m58.7m61.4m71.9m70.6m

General and administrative expense

3.8m2.3m2.9m3.4m3.7m3.9m5.8m5.3m4.9m5.8m6.9m6.7m9.0m12.5m10.4m

Operating expense total

9.9m7.8m9.6m10.9m10.9m19.7m26.0m36.2m36.2m65.8m50.7m65.5m70.4m84.5m81.0m

EBIT

(9.9m)(7.8m)(9.6m)(10.9m)(10.9m)(19.7m)(26.0m)(36.2m)(36.2m)(45.0m)(22.1m)(24.2m)(24.5m)(35.7m)(27.8m)

Interest expense

19.0k50.4k56.0k96.0k116.0k139.0k234.0k

Interest income

19.0k50.4k56.0k96.0k116.0k139.0k234.0k270.0k219.0k435.0k608.0k842.0k1.1m1.6m1.8m

Net Income

(9.7m)(7.6m)(9.3m)(10.7m)(10.7m)(19.5m)(25.8m)(35.8m)(36.3m)(44.5m)(21.5m)(23.1m)(23.4m)(34.1m)(26.0m)

Akebia Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

32.8m49.8m187.3m70.2m

Accounts Receivable

48.0k933.0k34.2m

Inventories

1.5m2.6m2.2m

Current Assets

110.5m141.0m296.3m358.4m

PP&E

209.9k540.0k2.6m3.6m

Total Assets

111.0m142.9m300.2m364.2m

Accounts Payable

2.0m2.3m2.0m7.0m

Current Liabilities

6.9m11.9m114.3m144.3m

Total Liabilities

232.1m244.9m

Additional Paid-in Capital

205.0m292.8m365.3m493.8m

Retained Earnings

(100.7m)(161.4m)(297.1m)(374.0m)

Total Equity

104.1m131.0m68.1m119.3m

Financial Leverage

1.1 x1.1 x4.4 x3.1 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

126.3m95.4m49.7m27.9m76.2m66.7m43.4m46.2m65.8m87.3m125.4m89.6m158.2m163.5m162.4m

Accounts Receivable

119.4k114.0k57.0k74.0k48.0k14.0k35.9m132.0k688.0k

Current Assets

133.7m126.1m119.8m102.7m155.0m158.8m219.5m192.5m165.1m255.1m332.4m333.9m437.0m407.4m397.5m

PP&E

181.0k204.9k404.0k398.0k479.0k629.0k1.8m2.7m2.9m2.9m3.4m3.7m3.7m3.8m

Total Assets

134.0m126.4m120.2m103.5m155.7m159.6m221.4m195.6m169.1m259.3m336.8m338.6m442.7m413.8m403.8m

Accounts Payable

2.1m1.5m3.0m4.3m2.4m5.3m2.4m5.1m8.5m15.1m10.2m8.7m17.9m4.8m12.7m

Current Liabilities

6.1m4.8m6.5m8.8m5.9m14.2m13.4m20.9m26.1m133.5m181.6m151.4m151.4m164.4m177.4m

Long-term debt

7.4k6.4k

Total Debt

7.4k6.4k

Total Liabilities

6.2m4.8m6.6m8.9m5.9m14.2m53.7m62.3m68.4m228.6m279.8m238.7m245.6m247.9m261.3m

Additional Paid-in Capital

201.2m202.5m204.0m206.1m272.0m287.1m355.1m356.2m360.0m372.5m420.4m486.4m591.9m594.7m597.3m

Retained Earnings

(81.0m)(90.3m)(111.4m)(122.1m)(141.5m)(187.2m)(223.0m)(259.3m)(341.7m)(363.2m)(386.3m)(394.2m)(428.3m)(454.3m)

Total Equity

127.9m121.6m113.6m94.6m149.8m145.4m167.8m133.3m100.7m30.6m57.0m99.9m197.1m165.9m142.5m

Financial Leverage

1 x1 x1.1 x1.1 x1 x1.1 x1.3 x1.5 x1.7 x8.5 x5.9 xwdxefcqufszuzezftuxetqsqxt3.4 x2.2 x2.5 x2.8 x

Akebia Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(37.0m)(60.7m)(135.7m)(76.9m)

Depreciation and Amortization

49.4k96.0k296.0k617.0k

Accounts Receivable

87.0k(393.0k)

Inventories

(773.0k)(1.0m)428.0k

Accounts Payable

4.1m231.0k(274.0k)5.0m

Cash From Operating Activities

(27.5m)(52.4m)57.9m(56.2m)

Purchases of PP&E

(229.0k)(414.0k)(2.7m)(1.6m)

Cash From Investing Activities

(65.4m)(13.7m)12.7m(177.3m)

Cash From Financing Activities

104.4m83.1m66.9m116.2m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(9.7m)(10.7m)(21.4m)(40.9m)(25.8m)(61.6m)(36.3m)(44.5m)(66.1m)(89.2m)(23.4m)(57.5m)(83.5m)

Depreciation and Amortization

8.1k50.0k85.0k78.0k253.0k420.0k199.0k413.0k638.0k

Accounts Receivable

15.9k114.0k57.0k74.0k48.0k34.0k(1.6m)34.1m33.5m

Accounts Payable

1.9m1.5m3.0m4.3m(987.0k)7.3m2.4m2.8m8.5m15.1m8.2m6.7m10.9m(2.2m)5.7m

Cash From Operating Activities

(6.0m)(20.5m)(29.5m)(9.5m)14.8m(39.8m)(20.3m)(11.3m)(23.8m)

Purchases of PP&E

(142.0k)(227.0k)(342.0k)(1.4m)(575.0k)(1.2m)(296.0k)(469.0k)(776.0k)

Cash From Investing Activities

5.4m(871.0k)(15.3m)(55.2m)(124.0m)(169.0m)12.4m8.9m19.9m

Cash From Financing Activities

105.8m64.8m78.8m61.1m47.2m111.0m95.9m96.1m96.5m

Akebia Therapeutics Ratios

USDY, 2018

Financial Leverage

2.8 x
Report incorrect company information

Akebia Therapeutics Employee Rating

3.411 votes
Culture & Values
3.7
Work/Life Balance
4.1
Senior Management
3.9
Salary & Benefits
3.7
Career Opportunities
3.7
Source